Dr. GUSTAVO AGUIRRE-CHANG Substack

Share this post

User's avatar
Dr. GUSTAVO AGUIRRE-CHANG Substack
FIRST PROTOCOL AND THERAPEUTIC TEST WITH TENOFOVIR DF/ EMTRICITABINE (TRUVADA or generic) TO ASSIST THE DIAGNOSIS OF VIRAL PERSISTENCE IN POST ACUTE COVID SYNDROME (PACS) OR LONG COVID.

FIRST PROTOCOL AND THERAPEUTIC TEST WITH…

Dr. Gustavo Aguirre-Chang
Jan 4, 2023
11

Share this post

User's avatar
Dr. GUSTAVO AGUIRRE-CHANG Substack
FIRST PROTOCOL AND THERAPEUTIC TEST WITH TENOFOVIR DF/ EMTRICITABINE (TRUVADA or generic) TO ASSIST THE DIAGNOSIS OF VIRAL PERSISTENCE IN POST ACUTE COVID SYNDROME (PACS) OR LONG COVID.

If there is a response to treatment, the presence of Viral Persistence is supported. We also indicate it for Post-Vaccine COVID Syndrome (PVACS) or Post-Vaccine Persistent Symptoms.

Read →
Comments
User's avatar
© 2025 Gustavo Aguirre Chang
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share